Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

T0050000

Terbutaline sulfate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Terbutaline hemisulfate salt, 2-t-Butylamino-1-(3,5-dihydroxyphenyl)ethanol, 5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol hemisulfate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
C12H19NO3 · 1/2H2SO4
CAS Number:
23031-32-5
Molecular Weight:
274.32
MDL number:
MFCD00079584
UNSPSC Code:
41116107
PubChem Substance ID:
329826582
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

terbutaline

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c2cc(O)cc(O)c2

InChI

1S/2C12H19NO3.H2O4S/c2*1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8;1-5(2,3)4/h2*4-6,11,13-16H,7H2,1-3H3;(H2,1,2,3,4)

InChI key

KFVSLSTULZVNPG-UHFFFAOYSA-N

Gene Information

human ... ADRB2(154)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Terbutaline sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H361,H370

Hazard Classifications

Repr. 2 - STOT SE 1

Target Organs

Cardio-vascular system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Adel H Mansur et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 51(10), 1076-1082 (2014-07-16)
Long-term subcutaneous or intravenous infusion of terbutaline has been used to stabilize asthma in patients enduring frequent hospital admissions due to severe asthma despite maximum therapy. However, this treatment is not supported by significant body of evidence. To study long-term
John P Elliott et al.
The Journal of reproductive medicine, 58(3-4), 123-131 (2013-04-02)
Beta2-adrenergic agonist medications such as albuterol and terbutaline are often prescribed during pregnancy to treat conditions such as asthma, pulmonary disease, preterm labor, or acute non-reassuring fetal heart rate abnormalities during labor. Recently a review article questioned the safety of
F Lam et al.
Obstetrical & gynecological survey, 53(11 Suppl), S85-S95 (1998-11-13)
beta-mimetics have been prescribed by physicians to arrest or prevent premature labor for more than 20 years. Although not approved by the Food and Drug Administration (FDA) for tocolytic use, terbutaline sulfate has been the most widely prescribed beta-mimetic in
C H Scoggin
Clinical therapeutics, 6(5), 603-612 (1984-01-01)
Terbutaline sulfate, a relatively selective beta2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Studies have shown that when administered via an aerosol, terbutaline has a rapid onset, a prolonged duration of action, and
Srinivas R B Behara et al.
Journal of pharmaceutical sciences, 103(2), 465-477 (2013-12-07)
High-efficiency dry powder inhalers (DPIs) were developed and tested for use with carrier-free formulations across a range of different inhalation flow rates. Performance of a previously reported DPI was compared with two new designs in terms of emitted dose (ED)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service